CHF #13 Relief 40 Softgels

CHF #13

Relief

A combination of modern science and traditional wisdom, CHF #13 Relief disperses quickly to provide targeted support for muscle and joint comfort. Turmeric and Boswellia extracts are combined in a black sesame oil base using patented technology to swiftly inhibit cyclooxygenase and lipoxygenase receptors.

CHF #13 Relief is a novel formulation that combines bioactive ingredients from turmeric (Curcuma longa), Indian frankincense (Boswellia serrata), and sesame seed oil with bio-enhancing technology to rapidly distribute the active components. The combination of turmeric and Boswellia has been clinically studied for support of muscle and joint comfort.

Curcumin– is a phenolic phytochemical derived from turmeric, a root used in Chinese and Ayurvedic herbology and one of the most extensively investigated therapeutic compounds of natural origin. The mechanisms underlying curcumin’s effects are diverse and have not been fully elucidated, but it is well-known that curcumin has powerful antioxidant activity and exerts a wide spectrum of biological activities related to a healthy inflammatory response. At cellular and molecular levels, curcumin has been shown to inhibit the eicosanoid pathway enzymes cyclooxygenase (COX) and lipoxygenase (LOX) that are intimately involved in the inflammatory process. The regulation of COX and LOX enzymes may be the key mechanism underlying the beneficial effects demonstrated by curcumin for support of muscle and joint comfort. Meta-analyses of data from randomized controlled trials in subjects with underlying conditions, primarily osteoarthritis (OA), suggest supplementation of curcumin as an effective and safe strategy for managing pain-related symptoms.

Boswellia- the gum resin of Boswellia has a long history of Ayurvedic use, and over the last thirty years it has gained attention in the Western world resulting in the development of standardized extracts to support muscle and joint comfort. Boswellic acids have been shown to inhibit the activity of 5-LOX, the enzyme that catalyzes the formation of pro-inflammatory leukotrienes from arachidonic acid. The safety and efficacy of formulations containing a combination of boswellic acid and curcumin have also been evaluated, with synergistic interactions thought to be of benefit because of the variations in biologically active molecules that have inhibitive actions on both the COX and LOX pathways. In a 12-week clinical trial, results suggested that curcumin combined with boswellic acid had a higher level of effect on joint pain, morning stiffness, and the limitations of physical function than curcumin alone.

Sesame– oils and extracts of sesame seeds are used widely in food, in slaves for medicinal purposes, or as vehicles for delivering active compounds both orally and topically. Sesamin, the main lignin component of sesame seeds, has been reported to influence a decrease in pro-inflammatory prostaglandins and leukotrienes.

CHF #13 Relief is a clinically studied formulation featuring 95% curcuminoid turmeric rhizome extract and Bospure® Boswellia extract standardized to >10% AKBA delivered in a bio-enhancing sesame seed oil base to provide rapid-release support for joint and muscle comfort.